Literature DB >> 27819857

68Ga-PSMA Expression in Pseudoangiomatous Stromal Hyperplasia of the Breast.

Dharmender Malik1, Rajender K Basher, Bhagwant Rai Mittal, Tarun Kumar Jain, Amanjit Bal, Shrawan Kumar Singh.   

Abstract

Ga-labeled prostate-specific membrane antigen ligand PET-CT has emerged as a promising technique to evaluate the extent of disease in patients with prostate carcinoma. We are reporting a 63-year-old man with prostatic carcinoma subjected to Ga-prostate-specific membrane antigen ligand PET-CT for initial staging. In addition to the radiotracer uptake in known primary site (prostate), focal increased radiotracer uptake was also noticed in the left breast. Subsequent biopsy of the breast lesion revealed PASH (pseudoangiomatous stromal hyperplasia), which is a benign mesenchymal proliferative lesion that may present clinically as palpable mass requiring further evaluation to rule out malignancy.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 27819857     DOI: 10.1097/RLU.0000000000001445

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  8 in total

1.  [68Ga]Ga-PSMA-11 in prostate cancer: a comprehensive review.

Authors:  Frédéric Bois; Camille Noirot; Sébastien Dietemann; Ismini C Mainta; Thomas Zilli; Valentina Garibotto; Martin A Walter
Journal:  Am J Nucl Med Mol Imaging       Date:  2020-12-15

Review 2.  Management of Incidental Breast Lesions Detected at Nuclear Medicine Examinations.

Authors:  W Tania Rahman; Colleen H Neal; Alexis Virginia Nees; Richard K J Brown
Journal:  Radiol Imaging Cancer       Date:  2020-03-20

3.  Differentiating benign and malignant pancreatic masses: Ga-68 PSMA PET/CT as a new diagnostic avenue.

Authors:  Venkata Subramanian Krishnaraju; Rajender Kumar; Bhagwant Rai Mittal; Vishal Sharma; Harjeet Singh; Ritambhra Nada; Amanjit Bal; Manish Rohilla; Harmandeep Singh; Surinder S Rana
Journal:  Eur Radiol       Date:  2020-10-01       Impact factor: 5.315

Review 4.  Targeting PSMA by radioligands in non-prostate disease-current status and future perspectives.

Authors:  Philipp Backhaus; Benjamin Noto; Nemanja Avramovic; Lena Sophie Grubert; Sebastian Huss; Martin Bögemann; Lars Stegger; Matthias Weckesser; Michael Schäfers; Kambiz Rahbar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-01-15       Impact factor: 9.236

Review 5.  Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging.

Authors:  Sara Sheikhbahaei; Ali Afshar-Oromieh; Matthias Eiber; Lilja B Solnes; Mehrbod S Javadi; Ashley E Ross; Kenneth J Pienta; Mohamad E Allaf; Uwe Haberkorn; Martin G Pomper; Michael A Gorin; Steven P Rowe
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-08-01       Impact factor: 9.236

6.  Prostate-specific membrane antigen expression in hepatocellular carcinoma: potential use for prognosis and diagnostic imaging.

Authors:  Yuri Tolkach; Diane Goltz; Anika Kremer; Hojjat Ahmadzadehfar; Dominik Bergheim; Markus Essler; Marnix Lam; Bart de Keizer; Hans-Peter Fischer; Glen Kristiansen
Journal:  Oncotarget       Date:  2019-06-25

7.  Nonspecific Uptake of 68Ga-Prostate-Specific Membrane Antigen in Diseases other than Prostate Malignancy on Positron Emission Tomography/Computed Tomography Imaging: A Pictorial Assay and Review of Literature.

Authors:  Dharmender Malik; Apurva Sood; Bhagwant Rai Mittal; Harmandeep Singh; Rajender Kumar Basher; Jaya Shukla; Anish Bhattacharya; Shrawan Kumar Singh
Journal:  Indian J Nucl Med       Date:  2018 Oct-Dec

Review 8.  Molecular imaging reporting and data systems (MI-RADS): a generalizable framework for targeted radiotracers with theranostic implications.

Authors:  Rudolf A Werner; Ralph A Bundschuh; Lena Bundschuh; Mehrbod S Javadi; Takahiro Higuchi; Alexander Weich; Sara Sheikhbahaei; Kenneth J Pienta; Andreas K Buck; Martin G Pomper; Michael A Gorin; Constantin Lapa; Steven P Rowe
Journal:  Ann Nucl Med       Date:  2018-08-14       Impact factor: 2.668

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.